A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma.

@article{Schwartzentruber2009API,
  title={A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma.},
  author={Douglas J. Schwartzentruber and Deanna Lawson and Jan Richards and Robert M Conry and David Miller and J Triesman and Fawaz Gailani and Lee B. Riley and Don Vena and Patrick Hwu},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 18_suppl},
  pages={CRA9011}
}
CRA9011 Background: In a phase II study, 13 (42%) of 31 patients with metastatic melanoma receiving high-dose (HD) IL-2 plus gp100:209-217(210M) peptide experienced objective responses (S.A. Rosenberg, et al, Nature Medicine 4: 321-327, 1998). Other studies showed a lower response rate (RR) but no randomized studies have been done. METHODS A prospective randomized phase III trial was conducted at 21 centers with 185 patients. Eligibility: stage IV or locally advanced stage III cutaneous… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Strategies for Cancer Vaccine Development

Journal of biomedicine & biotechnology • 2010
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…